Altacor (United Kingdom) a commercial-stage ophthalmic specialty pharmaceutical company focused on ocular surface disease and glaucoma, closed a $3M Series C bringing the total financing to $5.4M. Participants include NVM Private Equity, Enterprise Ventures, Beringea and Esperante Ventures.